

Department of Hematology & Hematopoietic Cell Transplantation
Hematologic Malignancies Research Institute

May 21, 2024

Eileen P. Smith, M.D.
Francis and Kathleen McNamara Distinguished Chair Hematology
& Hematopoietic Cell Transplantation

Guido Marcucci, M.D.
Vice Chair

Stephen J. Forman, M.D.
Director, Hematologic Malignancies Research Institute

TRANSPLANTATION CENTER
Ryotaro Nakamura, M.D.
Director

CEHR FAMILY CENTER FOR LEUKEMIA RESEARCH
Guido Marcucci, M.D. Anthony Stein, M.D.
Director Co-Director

JUDY AND BERNARD BRISKIN CENTER FOR MULTIPLE MYELOMA
Amrita Krishnan, M.D.
Director

GENE THERAPY CENTER
John Zaia, M.D. Kevin Morris, Ph.D.
Director Co-Director

TONI STEPHENSON LYMPHOMA CENTER
Larry Kwak, M.D., Ph.D. Alexey Danilov, M.D., Ph.D.
Director Co-Director

CELLULAR IMMUNOTHERAPY CENTER
Stephen J. Forman, M.D. Christine Brown, Ph.D.
Director Co-Director

SURVIVORSHIP CENTER
Saro Armenian, DO, MPH
Director

Monzr Al Malki, M.D.
Director, Unrelated Donor BMT Program

Joseph Alvarnas, M.D.
Alexandra Levine, M.D., M.A.C.P.
Steven T. Rosen, M.D.
Tanya Siddiqi, M.D.
Myo Htut, M.D.
Ahmed Aribi, M.D.
Michael Rosenzweig, M.D.
Nitya Nathwani, M.D.
L. Elizabeth Budde, M.D., Ph.D.
Peter P. Lee, M.D.
Haris Ali, M.D.
Amandeep Salhotra, M.D.
Vinod Pullarkat, M.D.
Jasmine Zain, M.D.
Christiane Querfeld, M.D., Ph.D.
Matthew G. Mei, M.D.
Ibrahim Aldoss, M.D.
Alex Herrera, M.D.
Karamjeet Sandhu, M.D.
Shukaib Arslan M.D.
Andrew Artz, M.D.
Paul Koller, M.D.
Geoffrey Shouse, D.O., Ph.D.
Peter T. Curtin, M.D.
Idoroenyi Amanam, M.D.
Brian Ball, M.D.
Salman Otoukesh, M.D.
James Godfrey, M.D.
Hoda Pourhassan, M.D. Scott
Goldsmith, M.D. Murali
Janakiram, M.D. Vaibhav
Agrawal, M.D. John Baird,
M.D.
Swetha Kambhampati, M.D.
Tycel Phillips, M.D.
Avyakta Kallam, M.D.
Niloufer Khan, M.D.
Sarah Lee, M.D.
Sandra Thomas, Ph.D.
Don J. Diamond, Ph.D.
De-fu Zeng, M.D.
Ya-Huei Kuo, Ph.D.
Vu Ngo, Ph.D.
Ling Li, Ph.D.

CITY OF HOPE – KAISER PERMANENTE
Ricardo T. Spielberger, M.D.
Director

Firoozeh Sahebi, M.D.
Ji-lian Cai, M.D. Len Farol, M.D.
Joshua Mansour, M.D., Yazeed Samara, M.D.

HISTOCOMPATIBILITY LABORATORY
Ketevan Gendzekhadze, Ph.D.
Director

To Whom It May Concern:

At the request of my colleague, Dr. Irving Wiseman, I am writing this note related to his CIRM application and the question of the comparative purity of stem cell enrichment utilizing methodologies that he and his colleagues that developed over the years, compared to the current standard CD34 enrichment procedures that are occasionally used in clinical stem cell therapies. My impression from following his work over the years, as well as the medical literature related to the treatment of metastatic breast cancer, is that the methodologies he has developed do lead to a more enriched population of purified stem cells with the capacity for multilineage differentiation, and importantly, this approach also leads to the depletion of contaminating tumor cells which could contribute to relapse after treatment. The depletion of tumor cells from the stem cell graft eliminates this is a potential source of failure after treatment and allows the study to separate recurrent disease from what is infused with the graft, from the body burden of cancer at the time of treatment.

If you have any questions, please let me know.

Sincerely



Stephen J. Forman, M.D.
Professor and Staff Physician
Department of Hematology and
Hematopoietic Cell Transplantation
Department of Medical Oncology and Therapeutics Research